Cimzia (certolizumab pegol)

Manufacturer:
UCB, Inc.
Route of Administration: 
Subcutaneous
Site of Care:
Outpatient
Website: 
  • Manufacturer Website
phone: 
1-866-424-6942

Approved Indication:

  • reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
  • treatment of adults with moderately to severely active rheumatoid arthritis/strong>
  • treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
  • treatment of adult patients with active psoriatic arthritis
  • treatment of adults with active ankylosing spondylitis
  • treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation
  • treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Conditions:

  • Ankylosing Spondylitis
  • Crohn’s Disease
  • Juvenile Idiopathic Arthritis
  • Non-Radiographic Axial Spondyloarthritis
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis

Therapeutic Area:

  • Dermatology
  • Gastroenterology
  • Rheumatology